


How flu vaccines get to you

The vaccine-manufacturing process begins when the World Health Organization is notified that a research center has detected a virus strain that differs significantly from others that are circulating. The new virus then is sent to one of four "collaborating centers" around the world for analysis and vaccine formulation, including the U.S. Centers for Disease Control and Prevention in Atlanta.



Developing a new vaccine


The development of a new influenza vaccine starts when WHO obtains the new strain and adapts it for vaccine manufacturing

- 1 Vaccine virus preparation**
The new virus is mixed with a standard laboratory virus to make the vaccine less dangerous and better able to grow in a chicken egg
- 2 Test vaccine virus**
The hybrid vaccine virus is tested to make sure it is truly a vaccine, that it is safe and that it grows in eggs

1 2 Vaccine production with chicken eggs

After the hybrid virus has been tested in different growing conditions in eggs, this process is done to thousands of eggs and produces several hundred or thousand liters of purified virus protein, or antigen, which is the active ingredient in the vaccine.


A The vaccine virus is injected into a 9- to 12-day-old fertilized egg and incubated for two to three days; during this time the virus multiplies



Vaccine virus

Embryo


B After incubation, the egg white contains millions of vaccine viruses, which are harvested, and then separated from the egg white



Vaccine virus multiplied

Virus is spun to separate it from the egg white


C The desired proteins of the virus are purified, tested and eventually bottled as a vaccine




INFLUENZA VIRUS VACCINE

- 3 Quality control**
Manufacturers test each batch of vaccine with the WHO reagents
- 4 Vaccine packaging**
The vaccine is diluted to the proper concentration of antigen, packaged in vials or syringes and labeled; some are tested for sterility, concentration and safety
- 5 Clinical studies**
Vaccine is tested to make sure it performs as expected


FDA approval process




Application
Manufacturers must submit an application describing the vaccine, manufacturing method and quality control tests, as well as information about the vaccine's safety, animal tests results proving effectiveness and a plan for human clinical studies




Human clinical trials
Phase 1 Tests for safety and ability to stimulate an immune response in small number of subjects
Phase 2 Studies dose amount in hundreds of subjects
Phase 3 Provides additional safety data and vaccine effectiveness from tests in thousands of subjects



License application
A license application provides an FDA review team with information needed to make a risk/benefit assessment and to decide whether to recommend the vaccine for approval; the manufacturing facility also undergoes inspection and the vaccine is examined



Committee approval
After the review of a license application, the manufacturer and FDA present the information to a committee of non-FDA experts (the FDA Vaccines and Related Biological Products Advisory Committee) who advise the FDA on safety and efficiency



Distribution
Even after a license is granted, the FDA continues to examine the manufacturing process to ensure safety and effectiveness before the vaccine may be distributed; in some cases the vaccine must undergo a fourth phase of studies